Concomitant Drug Load Reduction During Adjunctive Cenobamate Therapy: Post-hoc Analysis of a Phase 3, Open-Label Study

被引：0
|
作者：
Aboumatar, Sami [1 ]
Ferrari, Louis [2 ]
Stern, Sean [2 ]
Wade, Clarence [2 ]
Weingarten, Mindl [2 ]
Connor, Gregory S. [3 ]
Rosenfeld, William E. [4 ]
机构：
[1] Austin Epilepsy Care Ctr, Austin, TX USA
[2] SK Life Sci Inc, Paramus, NJ USA
[3] Neurol Ctr Oklahoma, Tulsa, OK USA
[4] Comprehens Epilepsy Care Ctr Children & Adults, St Louis, MO USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202180
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P11-1.006
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study
    Aboumatar, Sami
    Ferrari, Louis
    Stern, Sean
    Wade, Clarence T.
    Weingarten, Mindl
    Connor, Gregory S.
    Rosenfeld, William E.
    EPILEPSY RESEARCH, 2024, 200
  • [2] Sustainability of seizure reduction and seizure control with adjunctive cenobamate: Post hoc analysis of a phase 3, open-label study
    Vossler, David G. G.
    Rosenfeld, William E. E.
    Stern, Sean
    Wade, Clarence T. T.
    Ferrari, Louis
    Kerr, Wesley T. T.
    Wechsler, Robert
    EPILEPSIA, 2023, 64 (10) : 2644 - 2652
  • [3] PREDICTORS OF SUSTAINABILITY OF RESPONSE WITH CENOBAMATE: POST-HOC SUBSET ANALYSIS OF A PHASE 3, OPEN-LABEL STUDY
    Stern, S.
    Wechsler, R.
    Kerr, W.
    Wade, C.
    Vossler, D. G.
    Rosenfeld, W. E.
    VALUE IN HEALTH, 2023, 26 (06) : S17 - S17
  • [4] Predictors of Sustainability of Response With Cenobamate: Post-hoc Subset Analysis of a Phase 3, Open-Label, Study
    Stern, Sean
    Wechsler, Robert
    Kerr, Wesley T.
    Wade, Clarence T.
    Vossler, David G.
    Rosenfeld, William E.
    NEUROLOGY, 2023, 100 (17)
  • [5] Number of seizure-free days with adjunctive cenobamate: post-hoc analysis of an open-label extension study
    Brandt, C.
    Fabo, D.
    Milovanovic, M.
    Alvarez-Baron, E.
    Thangavelu, K.
    Milanov, I.
    EPILEPSIA, 2023, 64 : 58 - 58
  • [6] Number of seizure-free days with adjunctive cenobamate: post-hoc analysis of an open-label extension study
    Brandt, C.
    Fabo, D.
    Milovanovic, M.
    Alvarez-Baron, E.
    Thangavelu, K.
    Milanov, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 171 - 171
  • [7] Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study
    Sperling, Michael R.
    Abou-Khalil, Bassel
    Aboumatar, Sami
    Bhatia, Perminder
    Biton, Victor
    Klein, Pavel
    Krauss, Gregory L.
    Vossler, David G.
    Wechsler, Robert
    Ferrari, Louis
    Kamin, Marc
    Grall, Mindy
    Rosenfeld, William E.
    NEUROLOGY, 2021, 96 (15)
  • [8] Efficacy of cenobamate by focal seizure subtypes: Post-hoc analysis of a phase 3, multicenter, open-label study
    Rosenfeld, William E.
    Ferrari, Louis
    Kamin, Marc
    EPILEPSY RESEARCH, 2022, 183
  • [9] Post-hoc Analysis of the Effects of Dose Reductions of Concomitant Clobazam in a Phase 3, Open-Label Study of Cenobamate for the Treatment of Uncontrolled Focal Seizures
    Abou-Khalil, Bassel
    Ferrari, Louis
    Klein, Pavel
    Kim, Jessica
    Krauss, Gregory L.
    Vossler, David G.
    Sperling, Michael R.
    Rosenfeld, William E.
    NEUROLOGY, 2021, 96 (15)
  • [10] Efficacy of Cenobamate by Concomitant Antiseizure Medications in Patients With Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study
    Klein, Pavel
    Vossler, David G.
    Krauss, Gregory L.
    Sperling, Michael R.
    Kamin, Marc
    Rosenfeld, William E.
    NEUROLOGY, 2021, 96 (15)
12345